Radiogenomics should be an integral part of drug development, according to Dr Korn who talks to ecancer about this evolving field at TAT 2015.

In the interview, Korn discusses how radiogenomics can be used to evaluate tumour response to molecularly targeted agents and how it improves on more traditional methods.